KIT and seminoma: Unfortunately, although seminomas may harbour activating KIT mutations, responses in clinical studies of the KIT tyrosine kinase inhibitor imatinib mesylate have been disappointing, with no complete or even partial remissions (Einhorn et al., 2006).